GESTIÓN EN SALUD PÚBLICA: Public Meeting: Interim Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act - 01/27/2021 | FDA

lunes, 7 de diciembre de 2020

Public Meeting: Interim Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act - 01/27/2021 | FDA

Public Meeting: Interim Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act - 01/27/2021 | FDA

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)